OFG
CLSD

Oxford Financial Group’s Clearside Biomedical CLSD Stock Holding History

Oxford Financial Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,122
Closed -$252K – 222
2020
Q4 		$252K Hold
6,122
– – 0.04% 157
2020
Q3 		$141K Hold
6,122
– – 0.02% 158
2020
Q2 		$173K Hold
6,122
– – 0.03% 153
2020
Q1 		$156K Buy
+6,122
New +$226K 0.03% 153

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxford Financial Group's CLSD Position: Q1 2021 in Review

Oxford Financial Group sold out of Clearside Biomedical (CLSD) in Q1 2021, closing a stake of 6,122 shares — an estimated $252K sold.

Oxford Financial Group first reported a position in CLSD in Q1 2020 and held it in 4 quarters. The position peaked at $252K in Q4 2020. 51 funds tracked by Wall St. Rank hold CLSD as of Q1 2021.

  • Oxford Financial Group reported no remaining Clearside Biomedical position as of Q1 2021 after selling out during the quarter.
  • Oxford Financial Group sold 6,122 Clearside Biomedical shares in Q1 2021, an estimated $252K.
  • Oxford Financial Group first reported a position in Clearside Biomedical in Q1 2020 and held it in 4 quarters.
  • Oxford Financial Group's Clearside Biomedical position peaked at $252K in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2021.

Based on Oxford Financial Group's 13F filing for Q1 2021, filed 10 May 2021.